Printer Friendly

SYNERGEN TO BEGIN THREE NEW CLINICAL TRIALS

 SYNERGEN TO BEGIN THREE NEW CLINICAL TRIALS
 BOULDER, Colo., Dec. 6 /PRNewswire/ -- Synergen, Inc. (NASDAQ: SYGN)


announced today it has received permission from the Food and Drug Administration to begin testing ANTRIL(TM), its interleukin-1 receptor antagonist, in three new clinical indications. The company will initiate clinical trials in asthma, inflammatory bowel disease (IBD) and graft versus host disease (GVHD) within the next few weeks.
 The overproduction of interleukin-1 (IL-1) is implicated in many different medical conditions, including asthma, IBD and GVHD. Animal studies have indicated that ANTRIL blocks the inflammatory response in these three varied disorders.
 The new clinical trials are designed to evaluate the safety and therapeutic activity of ANTRIL in these three indications and to determine appropriate dosing and regimens of administration. ANTRIL is also being tested in four other indications: sepsis syndrome, rheumatoid arthritis, chronic myelogenous leukemia and in a clinical cachexia model.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals.
 -0- 12/6/91
 /CONTACT: Debra Catz Bannister, 303-938-6242, or Susan Eustes, 303-441-5512, both of Synergen/
 (SYGN) CO: Synergen, Inc. ST: Colorado IN: MTC SU: PDT


PS -- NY003 -- 9973 12/06/91 08:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 6, 1991
Words:197
Previous Article:TELIOS PHARMACEUTICALS EXPANDS TELIO-DERM(TM) CLINICAL TRIALS Wound Healing Product Shows Encouraging Results
Next Article:ECOGEN RECEIVES PROJECT GRANT
Topics:


Related Articles
SYNERGEN AND INSITE VISION ANNOUNCE COOPERATIVE AGREEMENT TO EVALUATE ANTRIL FOR OPHTHALMIC APPLICATIONS
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
SYNERGEN APPOINTS DIRECTOR OF QUALITY
SYNTEX-SYNERGEN JOINT VENTURE BEGINS ALS PHASE I STUDY
SYNERGEN DEDICATES NEW COMMERCIAL-SCALE MANUFACTURING PLANT
SYNERGEN COMPLETES PHASE III CLINICAL TRIAL ENROLLMENT FOR ANTRIL IN SEPSIS; 900 PATIENTS RECRUITED IN THE U.S., CANADA AND EUROPE
SYNERGEN BEGINS OPERATIONS IN JAPAN
NEW SYNERGEN SEPSIS TRIAL ENROLLS FIRST PATIENT; FOLLOW-UP TRIAL IN SEVERE SEPSIS PATIENTS BEGINS ON SCHEDULE
SYNTEX-SYNERGEN JOINT VENTURE ALS STUDY UNDERWAY
SYNERGEN'S ANTRIL SHOWS PROMISE IN RHEUMATOID ARTHRITIS; A SECOND PHASE II TRIAL TO START IN EUROPE IN EARLY 1994

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters